Phaseline

Companies › Taizhou Mabtech Pharmaceutical

Taizhou Mabtech Pharmaceutical: clinical trials, targets and expected readouts

5 active drug programs in 28 registered trials: 10 Phase 4, 9 Phase 2, 5 Phase 1, 4 Phase 3; Oncology, Immunology, Gastroenterology, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Infliximab
TNF-alpha inhibitor
TNFPhase 4Crohn Disease; Inflammatory Bowel Diseases; Ulcerative Colitis; Schizophrenia …Nov 2026
Enlituo®
EGFR inhibitor monoclonal antibody
EGFRPhase 3Colorectal Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)Oct 2029
Omalizumab (CMAB007)
Ig epsilon chain C region inhibitor
IGHEPhase 3Chronic Spontaneous Urticaria–
CMAB017–Phase 1Solid MalignanciesMay 2027
CMAB015
Interleukin-17A (IL-17A) inhibitor monoclonal antibody
IL17APhase 1Psoriasis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06059989InfliximabPhase 3Inflammatory DiseaseImmunologyJun 2025
NCT06365879Omalizumab (CMAB007)Phase 3Chronic Spontaneous UrticariaImmunologyJan 2026
NCT07254325CMAB015Phase 1PsoriasisImmunologyJun 2026
NCT04835506InfliximabPhase 4Crohn DiseaseImmunologySep 2026
NCT03819296InfliximabPhase 1Clinical Stage 0 Cutaneous Melanoma AJCC v8OncologyOct 2026
NCT05906576InfliximabPhase 4Crohn DiseaseImmunologyNov 2026
NCT06113913InfliximabPhase 4Inflammatory Bowel DiseasesImmunologyNov 2026
NCT03684278InfliximabPhase 2Acute PancreatitisGastroenterologyDec 2026
NCT05043870InfliximabPhase 4Crohn DiseaseImmunologyDec 2026
NCT04999228InfliximabPhase 4Ulcerative ColitisImmunologyDec 2026
NCT05689879InfliximabPhase 3SarcoidosisImmunologyJan 2027
NCT05180994InfliximabPhase 1Glaucoma Following SurgeryOphthalmologyMar 2027
NCT05660746InfliximabPhase 2Crohn DiseaseImmunologyMar 2027
NCT06933069CMAB017Phase 1Solid MalignanciesOncologyMay 2027
NCT06051253InfliximabPhase 4Crohn DiseaseImmunologyJun 2027
NCT05034536InfliximabPhase 2Metastatic MelanomaOncologyJun 2027
NCT05169593InfliximabPhase 4Crohn DiseaseImmunologyOct 2027
NCT04407247InfliximabPhase 1ColitisOncologyDec 2027
NCT05823532InfliximabPhase 4SchizophreniaPsychiatryMar 2028
NCT06453317InfliximabPhase 2Ulcerative ColitisImmunologyApr 2028
NCT06453317InfliximabPhase 2Ulcerative ColitisImmunologyApr 2028
NCT06136546InfliximabPhase 2Depressive Disorder, MajorPsychiatryAug 2028
NCT07683975InfliximabPhase 4Acute Kidney InjuryGenitourinaryJan 2029
NCT02714634InfliximabPhase 4Rheumatoid ArthritisImmunologyMar 2029
NCT07595276Enlituo®Phase 3Colorectal CancerOncologyOct 2029
NCT04305145InfliximabPhase 2Melanoma Stage IIIOncologyJun 2030
NCT07791745Enlituo®Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)OncologyAug 2032
NCT07791745Enlituo®Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)OncologyAug 2032

Targets

EGFR (1) TNF (1) IGHE (1) IL17A (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Johnson & Johnson (Janssen) Dizal Pharmaceuticals Chia Tai Tianqing Pharmaceutical Group Betta Pharmaceuticals Novartis Jiangsu Hansoh Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Companies built like this

Tanabe Pharma Beijing VDJBio Jiangsu Aosaikang Pharmaceutical Ganzhou Hemay Pharmaceutical Celltrion

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.